CVKD: Cadrenal Therapeutics, Inc. Stock

by  •  • Comments Off on CVKD: Cadrenal Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.06
Enterprise Value ($M) -1.35
Book Value ($M) 7.69
Book Value / Share 0.48
Price / Book 0.92
NCAV ($M) 7.67
NCAV / Share 0.48
Price / NCAV 0.92

Profitability (mra)
Return on Invested Capital (ROIC) -1.08
Return on Assets (ROA) -1.86
Return on Equity (ROE) -2.06

Liquidity (mrq)
Quick Ratio 10.27
Current Ratio 10.27

Balance Sheet (mrq) ($M)
Current Assets 8.49
Assets 8.52
Liabilities 0.83
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -7.63
Net Income -8.36

Cash Flow Statement (mra) ($M)
Cash From Operations -3.53
Cash from Investing -0.00
Cash from Financing 11.90

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
02-13 13G/A Murphy John Raymond 5.49 20.18
02-12 13G Pham Quang X 48.57

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 24,894 74,513 33.41
2024-05-01 21,405 62,394 34.31
2024-04-30 8,915 13,809 64.56
2024-04-29 45,570 30,081 151.49

(click for more detail)

Similar Companies
CSBR – Champions Oncology, Inc. CTXR – Citius Pharmaceuticals, Inc.
CUE – Cue Biopharma, Inc. CYCC – Cyclacel Pharmaceuticals, Inc.
CYCN – Cyclerion Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io